| Name | Title | Contact Details |
|---|
MicroSurgical Technology is a Redmond, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
With our focus on improving patient outcomes with evidence-based healing solutions, we develop, market and distribute biotechnology products to physicians, hospitals, clinics and all post-acute care settings. We are constantly seeking long-term partnerships with a focus on products that produce efficacious outcomes at a lower overall cost. Our products are primarily sold in the North American surgical tissue repair and advanced wound care markets.
Women In Need is a Portland, ME-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
St. Mary`s Healthcare offers a continuum of services designed to fulfill the total healthcare needs of the community, while being the lowest cost provider. In addition to our 143 bed hospital, a 160 bed nursing home and a 10 bed acute rehabilitation unit, St. Mary`s provides highly accessible healthcare through its seven offsite primary care centers and behavioral health service locations throughout two counties. We treat more than 290,000 outpatient visits a year. Founded by the Sisters of St. Joseph of Carondelet in 1903, and as a member of Ascension since 2002, St. Mary`s is dedicated to improving the health of the community with special attention to the poor and underserved. By addressing the spiritual, social, emotional and physical needs of our patients, we strive to provide an exceptional patient experience and a model community for our associates and medical staff.
Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.